Abstract: The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them.
Type:
Grant
Filed:
May 9, 2011
Date of Patent:
December 6, 2011
Assignee:
Aventis Pharma S.A.
Inventors:
Christian Viskov, Vesna Biberovic, Pierre Mourier, Luc Grondard
Abstract: A hyaluronic acid derivative, and methods of producing and using said derivative, the derivative comprising n repeating units and having the general structural formula (I), wherein, in at least one repeating unit, one or more of R1, R2, R3, R4 comprises an etherbound aryl/alkyl sulfone having the general structural formula (II), wherein R comprises an alkyl- or aryl-group, and otherwise R1, R2, R3, R4 are hydroxyl groups, OH.
Abstract: The present invention relates to a preventive/remedy for obesity, which has a hydroxypropylated starch as its active ingredient. Provided are materials for foods, drugs, etc. which can exhibit an effect of preventing/lessening the onset of various lifestyle related diseases, for example, an effect of preventing/ameliorating obesity, or preventing/ameliorating hyperlipidemia; have a high safety and a wide application range; and rarely damage their texture.
Abstract: The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
Type:
Grant
Filed:
January 30, 2009
Date of Patent:
December 6, 2011
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Young K. Chen, Erick Co, Prasuna Guntupalli, John D. Lawson, Wolfgang Reinhard Ludwig Notz, Jeffrey A. Stafford, Huong-Thu Ton-Nu
Abstract: An antibacterial agent having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is provided. Specifically, the antibacterial agent of the present invention having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is a caprazamycin derivative represented, for example, by the following general formula (II): wherein Me is a methyl group; and R1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms.
Type:
Grant
Filed:
February 11, 2009
Date of Patent:
November 15, 2011
Assignees:
Microbial Chemistry Research Foundation, Meiji Seika Kaisha, Ltd.
Abstract: The present invention relates to a process for spray drying uronic acid oligosaccharides and to a powder compositions thus obtained. Typically the powder composition comprises between 25 and 100 wt.% uronic acid oligosaccharide with a DP between 2 and 50 based on total weight of uronic acid, with and an average particle size between 20 ?m and 100 ?m.
Type:
Grant
Filed:
April 21, 2006
Date of Patent:
November 1, 2011
Assignee:
N.V. Nutricia
Inventors:
Martin Van Eert, Bernd Stahl, Antonie Van Baalen
Abstract: A method of treating a Th1-mediated disorder includes administering to a subject in need of the treatment an effective amount of a compound of the formula I: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; p is 1, 2, 3, or 4; and the Th1-mediated disorder is non-obese diabetes, Crohn's colitis, autoimmune hemolytic anemia, rheumatoid arthritis, autoimmune encephalitis, multiple sclerosis, or autoimmune myocarditis. Also disclosed is a pharmaceutical composition including a compound of formula I above and a pharmaceutically acceptable carrier.
Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.
Type:
Grant
Filed:
April 23, 2008
Date of Patent:
November 1, 2011
Assignee:
CyDex Pharmaceuticals, Inc.
Inventors:
Gerold L. Mosher, James D. Pipkin, Douglas B. Hecker
Abstract: The novel crystalline and polymorphic forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-?-D-mannopyranosyloxy)-phenyl] hexane have advantageous properties and can be used in pharmaceutical and dermatological compositions.
Type:
Grant
Filed:
June 14, 2011
Date of Patent:
October 18, 2011
Assignee:
Revotar Biopharmaceuticals AG
Inventors:
Ewald M. Aydt, Remo Kranich, Karin Vollhardt, Gerhard Wolff
Abstract: Processes are disclosed that use 3?-reversibly terminated nucleoside triphosphates to analyze DNA for purposes other than sequencing using cyclic reversible termination. These processes are based on the unexpected ability of terminal transferase to accept these triphosphates as substrates, the unexpected ability of polymerases to add reversibly and irreversibly terminated triphosphates in competition with each other, the development of cleavage conditions to remove the terminating group rapidly, in high yield, and without substantial damage to the terminated oligonucleotide product, and the ability of reversibly terminated primer extension products to capture groups. The presently preferred embodiments of the disclosed processes use a triphosphate having its 3?-OH group blocked as a 3?-ONH2 group, which can be removed in buffered NaNO2 and use variants of Taq DNA polymerase, including one that has a replacement (L616A).
Type:
Grant
Filed:
March 27, 2009
Date of Patent:
October 11, 2011
Inventors:
Steven Albert Benner, Daniel Hutter, Nicole Aurora Leal, Fei Chen
Abstract: A method for detecting a Norwalk-Like Virus (NLV) in a biological sample, comprising the steps of: obtaining a biological sample suspected of containing a NLV; contacting the biological sample with at least one human histo-blood group antigen to allow formation of a complex of the NLV with the antigen; and detecting the antigen-NLV complex. The antigen-NLV complex can be detected by contacting the NLV-antigen complex with a NLV antibody that binds at an epitope of the NLV, and detecting the NLV antibody. The invention also includes a method for identifying compounds, and the compounds, that can inhibit the binding between a Norwalk-Like Virus (NLV) and a histo-blood group antigen.
Type:
Grant
Filed:
February 29, 2008
Date of Patent:
September 27, 2011
Assignees:
Children's Hospital Medical Center, INSERM
Abstract: The present invention relates to a method for preparing the glucopyranosyloxypyrazole derivatives which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications, obesity or the like. A glucopyranosyloxypyrazole derivative can be easily and efficiently prepared by allowing a benzylpyrazole derivative represented by the general formula: wherein R1, R2, R3, R4 and R5 may be the same or different, for example each of them is a hydrogen atom, a halogen atom or an alkyl, alkoxy, arylmethyloxy group or the like, R6 is an alkyl group, for example R7 is a hydrogen atom or an alkyl, alkoxy, arylmethyloxy group or the like, to react with a compound represented by the general formula: wherein as an example, PG1 is a pivaloyl group or the like, as an example, X1 is a bromine atom or the like, therefore the present invention is extremely useful as a method for preparing pharmaceutical compounds.
Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.
Abstract: The invention concerns compounds of the general formula (I) in which the residues R1 to R7 have the meanings given in the application as well as methods for their preparation. The compounds are in particular suitable as substrates for RNA or DNA polymerases and can thus be incorporated into RNA or DNA oligonucleotides and are especially suitable for labelling and detecting nucleic acids or for DNA sequencing.
Abstract: A class of proteoglycans containing fucosylated acidic glycans, e.g., as produced by marine sponges and sea urchin embryos, have been found to stimulate selective proliferation of mammalian natural killer (NK) cells and ??T cells. These compounds are useful as pharmaceuticals, particularly as immunostimulants, e.g., in the treatment of cancer and viral infections.
Abstract: A process for the preparation of an orally administrable calcium composition comprising the steps of: (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range of 3 to 40 ?m, having a crystalline structure and having a surface area of 0.1 to 1.2 m2/g; (ii) mixing the calcium compound with a water-soluble diluent and an aqueous solution of a water soluble binder in a fluid bed granulation apparatus and dying the resulting mixture to produce a first granulate; (iii) optionally mixing the first granulate with one or more further components to produce a second granulate; and (iv) optionally compressing the first or second granulate to form tablets.
Abstract: The invention relates to agents that contain folic acid, vitamin B6 and vitamin B12, and to the use thereof in hyperhomocysteinemia for controlling homocysteine levels. The agents are mainly suitable for the preventive and acute treatment of vascular diseases, of pregnant women and neurodegenerative diseases and are particularly advantageous in cases where the homocysteine levels to be controlled are found in an individual suffering from renal failure or being treated with immune suppressors. The invention particularly relates to pharmaceutical agents and food supplements comprising a corresponding active ingredient combination and to agents in the form of commercial packages containing corresponding combination preparations or monopreparations for the combined use.
Abstract: The present invention, in one aspect, provides a method of inhibiting bacterial growth by contacting bacteria with an effective amount of at least one monosaccharide compound of formula (1) as described herein:
Type:
Grant
Filed:
December 20, 2006
Date of Patent:
August 2, 2011
Assignee:
Alchemia Limited
Inventors:
Wim Meutermans, Declan McKeveney, Johannes Zuegg, Rajaratnam Premraj, Craig Muldoon, Giang Thanh Le
Abstract: The present invention relates to a composition for preventing or treating diabetes or blood glucose control abnormality comprising gisenosides Rg3, Rg5, and Rk1 from natural substances; a use of a mixture comprising gisenosides Rg3, Rg5, and Rk1 for the manufacture of a medicament for preventing or treating diabetes or blood glucose control abnormality; or a method for preventing or treating diabetes or blood glucose control abnormality by administering a therapeutically effective amount of mixture comprising gisenosides Rg3, Rg5, and Rk1 to a subject. The present composition can effectively prevent or treat diabetes, blood glucose control abnormality, and complication thereof.
Type:
Grant
Filed:
March 17, 2006
Date of Patent:
July 26, 2011
Assignee:
Unigen, Inc.
Inventors:
Sung-Sick Woo, Dong-Seon Kim, Seon-Gil Do, Young-Chul Lee, Mi-Sun Oh, Ji-Min Cha, Jong-Han Kim, Tae-Woo Kim
Abstract: Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.
Type:
Grant
Filed:
February 29, 2008
Date of Patent:
July 19, 2011
Assignee:
Adamas Pharmaceuticals, Inc.
Inventors:
Jack Nguyen, Gregory T. Went, Paul Spence, Timothy J. Fultz, David Chernoff, Terry L. Burkoth, Rowan Chapman, Mickey S. Urdea